Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis - PubMed (original) (raw)

Clinical Trial

Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis

S Edwards et al. J Neurol Neurosurg Psychiatry. 1998 Jun.

Abstract

Background: Although the risk of clinical attacks of multiple sclerosis seems to be significantly increased with viral upper respiratory tract infections (URTI), serological evidence for the reported association remains controversial. In addition, although MRI is six to 10 times more sensitive than clinical exacerbations in indexing disease activity, any possible association between URTI and MRI activity has yet to be investigated.

Objectives: To examine the relation between URTI and disease activity, in multiple sclerosis patients participating in a placebo controlled trial of interferon beta-1a, as indexed both by clinical exacerbation rate and by the number and volume of gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) enhancing lesions on MRI. "At risk" periods were defined around symptomatic URTI, with or without serological confirmation.

Results: The relative risk of clinical relapse for serologically unconfirmed symptomatic URTI was 2.1 (p=0.004). Raised antiviral antibody titres conferred a relative risk of multiple sclerosis exacerbations that was 3.4 times higher than the "not at risk" periods (annual attack rates of 5.7 v 1.6, respectively, p=0.006). There was no definite relation between the number or the volume of active lesions on MRI and either symptomatic or serologically defined at risk periods.

Conclusions: These results confirm the previously reported association between viral infections and multiple sclerosis exacerbations and indicate that the relative risk may be even higher when viral infection is serologically confirmed. However, the results, perhaps because of the confounding effects of interferon beta-1a, do not provide convincing evidence of increased blood-brain barrier breakdown or inflammation during periods of virally induced immune stimulation.

PubMed Disclaimer

Cited by

Does multiple sclerosis have a zoonotic origin? Correlations with lymphocytic choriomeningitis virus infection.
Hogeboom C. Hogeboom C. Front Immunol. 2023 Jun 16;14:1217176. doi: 10.3389/fimmu.2023.1217176. eCollection 2023. Front Immunol. 2023. PMID: 37398653 Free PMC article. No abstract available.
Clinically Manifest Infections Do Not Increase the Relapse Risk in People with Multiple Sclerosis Treated with Disease-Modifying Therapies: A Prospective Study.
Miele G, Cepparulo S, Abbadessa G, Lavorgna L, Sparaco M, Simeon V, Guizzaro L, Bonavita S. Miele G, et al. J Clin Med. 2023 Jan 28;12(3):1023. doi: 10.3390/jcm12031023. J Clin Med. 2023. PMID: 36769670 Free PMC article.
Neurological manifestations of COVID-19: a retrospective observational study based on 1060 patients with a narrative review.
Negro A, Tortora M, Gemini L, de Falco A, Somma F, d'Agostino V. Negro A, et al. Acta Radiol. 2023 May;64(5):1950-1957. doi: 10.1177/02841851221138557. Epub 2022 Nov 30. Acta Radiol. 2023. PMID: 36451533 Free PMC article.
Respiratory issues in patients with multiple sclerosis as a risk factor during SARS-CoV-2 infection: a potential role for exercise.
Razi O, Teixeira AM, Tartibian B, Zamani N, Knechtle B. Razi O, et al. Mol Cell Biochem. 2023 Jul;478(7):1533-1559. doi: 10.1007/s11010-022-04610-1. Epub 2022 Nov 21. Mol Cell Biochem. 2023. PMID: 36411399 Free PMC article. Review.
Long-term outcome after COVID-19 infection in multiple sclerosis: a nation-wide multicenter matched-control study.
Bsteh G, Assar H, Gradl C, Heschl B, Hiller MS, Krajnc N, Di Pauli F, Hegen H, Traxler G, Leutmezer F, Wipfler P, Zulehner G, Guger M, Enzinger C, Berger T; AUT-MuSC-19 investigators. Bsteh G, et al. Eur J Neurol. 2022 Jun 25:10.1111/ene.15477. doi: 10.1111/ene.15477. Online ahead of print. Eur J Neurol. 2022. PMID: 35751475 Free PMC article.

References

1. Lancet. 1972 Aug 5;2(7771):280-1 - PubMed
1. Ann N Y Acad Sci. 1965 Mar 31;122:457-66 - PubMed
1. Science. 1980 Aug 22;209(4459):933-4 - PubMed
1. Ann Neurol. 1983 Mar;13(3):227-31 - PubMed
1. Lancet. 1985 Jun 8;1(8441):1313-5 - PubMed

Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis - PubMed (original) (raw)